Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation

Phase 3 Unknown 88 enrolled The Catholic University of Korea BLNH · collab

RandomizedSingle-groupQuadruple-blindPrevention

Summary

The purpose of this study is to compare the efficacy and safety of palifermin on reducing mucositis for patients receiving autologous or allogeneic stem cell transplantation with supportive care.

Timeline

Start: 2015-01
Primary completion: 2015-03
Completion: 2015-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Palifermin	Protein / enzyme biologic	60 ug/kg	—

Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation

Summary

Timeline

Drugs

Indications